SATSUMA PHARMACEUTICALS

South San Francisco, CA, May 18, 2023 - Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a development-stage biopharmaceutical company today announced that its 505(b)(2) new drug application (NDA)..... We are a development-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions. Our initial product candidate is STS101 (dihydroergotamine (DHE) nasal powder), which we are focused on developing as an important and differentiated therapeutic option for the acute treatment of migraine... At Satsuma Pharmaceuticals, our mission is to create, develop and commercialize innovative therapeutic products that meaningfully improve the lives of people living with migraine and other debilitating conditions.

Also known as: Satsuma Pharmaceuticals, Inc.

Primary location: Durham United States